Castle Biosciences, Inc. (CSTL) Q2 FY26 Earnings Call

Strong TissueCypher growth drove a $20 million guidance increase, but lower margins and measured Advanced ADTX rollout remain key offsets.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-30
Length45 minutes
EPS$-0.07
Revenue$103.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All CSTL earnings ยท Back to CSTL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.